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VH replacement refers to RAG-mediated secondary recombination of the IgH genes, which
renews almost the entireVH gene coding region but retains a short stretch of nucleotides as
aVH replacement footprint at the newly generatedVH–DH junction.To explore the biological
significance of VH replacement to the antibody repertoire, we developed a Java-based VH
replacement footprint analyzer program and analyzed the distribution of VH replacement
products in 61,851 human IgH gene sequences downloaded from the NCBI database.
The initial assignment of the VH, DH, and JH gene segments provided a comprehensive
view of the human IgH repertoire.To our interest, the overall frequency of VH replacement
products is 12.1%; the frequencies of VH replacement products in IgH genes using differ-
ent VH germline genes vary significantly. Importantly, the frequencies of VH replacement
products are significantly elevated in IgH genes derived from different autoimmune dis-
eases, including rheumatoid arthritis, systemic lupus erythematosus, and allergic rhinitis,
and in IgH genes encoding various autoantibodies or anti-viral antibodies. The identified
VH replacement footprints preferentially encoded charged amino acids to elongate IgH
CDR3 regions, which may contribute to their autoreactivities or anti-viral functions. Analy-
ses of the mutation status of the identified VH replacement products suggested that they
had been actively involved in immune responses. These results provide a global view of
the distribution of VH replacement products in human IgH genes, especially in IgH genes
derived from autoimmune diseases and anti-viral immune responses.
Keywords: B-cell, antibody, IgH genes, cryptic RSS,VH replacement,VH replacement footprint, autoimmune disease,
anti-viral response
INTRODUCTION
To protect our body from various infectious agents, the adap-
tive immune system has evolved the capability to generate a vast
number of antibody (Ab) specificities through somatic rearrange-
ment of previously separated variable (V), diversity (D) (for heavy
chain only), and joining (J) gene segments to form the variable
domain exons of immunoglobulin genes (1–3). V(D)J recombi-
nation is catalyzed by a pair of recombination activating gene
products (RAG1 and RAG2) (4–6). Specific joining of the V, D, and
J gene segments is directed by the recombination signal sequences
(RSS) flanking each rearranging gene segment (7). The RSS is
composed of a highly conserved heptamer (5’-CACTGTG-3’) and
a nonamer (5’-ACAAAAACC-3’) separated by a non-conserved
spacer region with either 12 or 23 bp in length (7–9). There are
Abbreviations: aa, amino acid; cRSS, cryptic recombination signal sequence; EBV,
Epstein–Barr virus; HBV, hepatitis virus B; HCV, hepatitis virus C; HIV, human
immunodeficiency virus; RA, rheumatoid arthritis; RA, rheumatoid arthritis;
RAG, recombination activating gene products; SLE, systemic lupus erythematosus;
VHRFA, VH replacement footprint analyzer.
44 functional VH genes, 27 DH genes, and 6 JH genes within the
human IgH locus. The diversified IgH repertoire is generated at
different levels, including the random recombination of V, D, and J
genes segments, imprecise processing of the coding-ends, addition
of non-template nucleotides by terminal deoxynucleotidyl trans-
ferase (TdT), random pairing of IgH with Igκ or Igλ light chains,
and later through somatic hypermutation and class switch recom-
bination during antigen dependent germinal center reaction (2).
Previous analyses of the IgH repertoire have provided important
information regarding the developmental process and function of
B lineage cells (10, 11). For examples, earlier studies on the expres-
sion and rearrangement status of IgH genes demonstrated that
IgH gene are rearranged sequentially during early B lineage cell
development, in which DH to JH rearrangements occurs prior to
VH to DJH rearrangements followed by rearrangement of the Igκ
and then Igλ light chain genes (12, 13). Analyses of the Ig gene
repertoires of different autoimmune diseases such as rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE) revealed
skewed usages of specific germline VH genes (14–16), unusually
long CDR3 regions within the IgH and IgL genes (17, 18), and
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accumulation of somatic hypermutation in the variable regions of
IgH and IgL genes (15, 19).
The random process of V(D)J recombination is essential for
generating a diverse IgH repertoire, however, it also produces non-
functional IgH genes or IgH genes encoding autoreactive antigen
receptors (2, 20). Early B lineage cells carrying non-functional IgH
rearrangements must re-initiate the V(D)J recombination process
to generate functional B-cell receptors (BCRs) for subsequent
development; on the other hand, B-cells expressing autoreactive
receptors will be removed from the repertoire through receptor
editing, clonal deletion, or anergy to establish central tolerance
(1, 21, 22). Receptor editing refers to RAG-mediated secondary
recombination of previously rearranged IgH or IgL genes (1, 21,
22). The organizations of the Igκ and Igλ loci allow continuous
secondary recombination by joining an upstream VL gene with a
downstream JL gene segment. The previously formed VLJL joints
are deleted during secondary recombination leaving no trace in
the newly formed VLJL junctions; the only indication of extensive
light chain gene editing is the elevated usage of the 3′ Jκ or Jλ genes
and the deletion of the Igκ locus (23, 24).
The unwanted IgH genes can also be changed through a RAG-
mediated VH replacement process using the cryptic recombina-
tion signal sequences (cRSSs) embedded within the framework-3
regions of previously rearranged VH genes (21, 22, 25). The con-
cept of VH replacement was originally proposed to explain the
observation that functional IgH genes were generated in mouse
pre-B-cell leukemia lines initially harboring non-functional IgH
rearrangements (26–28). Comparison of the functional IgH genes
versus the non-functional IgH rearrangements suggested a VH to
VHDJH recombination process mediated by the cRSS sites (26,
27). Subsequently, the occurrence of VH replacement had been
demonstrated in mouse models carrying knocked-in IgH genes
encoding anti-DNA Abs, anti-NP Abs, or non-functional IgH
genes in both alleles (29–34). Despite these findings, the natural
occurrence of VH replacement during early B-cell development in
mouse remains to be determined (35, 36).
Ongoing VH replacement in human B-cells had been found in
a human leukemia cell line, EU12, by detection of RAG-mediated
cRSS double stranded DNA breaks (DSBs) and by amplification
of different VH replacement excision circles (37). The detection of
DSBs at the VH3–cRSS borders in human bone marrow imma-
ture B-cells provided the first evidence for the natural occur-
rence of VH replacement during normal B-cell development in
humans (37). The occurrence of VH replacement in bone marrow
immature B-cells is consistent with the observation that RAG1
and RAG2 genes can be reinduced in these cells to catalyze IgL
gene editing (24, 38, 39). Our recent studies showed that VH
replacement occurs in the newly immigrated immature B-cells
in the peripheral blood of healthy donors, which can be fur-
ther induced through BCR-mediated signaling in Ref. (40). The
cRSS-mediated VH replacement was of particular interest because
the cRSS motifs are found in 40 out of 44 human VH germline
genes and in the majority of mouse VH germline genes (22, 41).
VH replacement renews almost the entire VH gene coding region
but retains a short stretch of nucleotides as a VH replacement
footprint at the VH–DH junction (37). Such footprints can be
used to identify VH replacement products through analysis of
IgH gene sequences. The initial analyses of 417 human IgH gene
sequences estimated that VH replacement products contribute
to about 5% of the normal IgH repertoire (37). Interestingly,
analyses of the amino acids encoded by the VH replacement
footprints revealed that these footprints preferentially contribute
charged amino acids into the IgH CDR3 regions, which is dif-
ferent from the low frequency of charged amino acids encoded
by human germline DH genes or N region sequences added by
TdT (37).
To explore the biological significance of VH replacement, we
developed a Java-based computer program and analyzed 61,851
human IgH gene sequences from the NCBI database to determine
the distribution of VH replacement products.
MATERIALS AND METHODS
DEVELOPMENT OF THE VH REPLACEMENT FOOTPRINT ANALYZER
PROGRAM
The VH replacement footprint analyzer (VHRFA) program was
developed using the NetBeans 7.01 IDE with Java development
kit (JDK) and tested under Windows, Mac OS X, and Ubuntu
Linux (42). The reference human VH germline gene sequences
were downloaded from the IMGT database to generate the library
of VH replacement footprints with different lengths. For the initial
test of the VHRFA program, we used 417 IgH sequences that had
been analyzed in our previous study to manually identify potential
VH replacement products (37, 43). The 61,851 human IgH gene
sequences were downloaded from the NCBI database on April
20, 2011.
ANALYSIS OF IgH GENE SEQUENCES AND IDENTIFICATION OF
POTENTIAL VH REPLACEMENT PRODUCTS USING THE VHRFA
PROGRAM
The IgH gene sequence files from NCBI database were first con-
verted into FASTA files and uploaded to the VHRFA program.
The VH, DH, and JH germline gene usages were assigned by auto-
matic submission of sequences in batches to the IMGT/V-Quest
program (http://www.imgt.org/IMGT_vquest/share/textes/) (44)
and the results were exported as Microsoft Excel files to a local
computer. Identical IgH gene sequences in the original NCBI data-
base were removed based on their VH–DH–JH junctions and the
remaining 39,438 unique human IgH gene sequences with iden-
tifiable VH, DH, and JH genes were further analyzed to identify
potential VH replacement products and calculate the frequencies
of VH replacement products in subsequent analyses. Briefly, the
IgH gene sequences with clear identifiable VH, DH, and JH genes
were analyzed to identify VH replacement footprints with 7, 6, 5,
4, and 3-mer VH replacement footprint motifs at their VH–DH
junction (N1) regions and DH–JH junction (N2) regions. The fre-
quency of VH replacement products was calculated by dividing
the number of IgH genes with VH replacement footprints in the
N1 regions with the total number of unique IgH gene sequences.
IgH genes with 7, 6, 4, and 3-mer VH replacement footprint motifs
within their N1 regions were also analyzed and discussed. The
positive prediction value with 95% confidence interval using the
6, 5, 4, and 3-mer VH replacement footprint motifs to assign VH
replacement products are 68, 59, 54, and 52%, respectively. In the
following comparison, the VH replacement products mainly refer
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to IgH genes with 5-mer VH replacement footprint within their
N1 regions.
The distribution of VH replacement products in IgH genes
derived from different keyword sub-categories were analyzed
based on the information linked to each sequence in the NCBI
GenBank files. The frequencies of VH replacement products with
pentameric footprints were used for all these comparisons. For
mutational analysis the IgH gene sequences had a minimum of
≥80% nucleotide similarity to the assigned germline VH gene
sequences.
STATISTICAL ANALYSIS
Statistical significance was determined by using either the two-
tailed Chi square test with Yates’ correction or the unpaired t -test.
p< 0.05 is considered statistically significant and p< 0.0001 is
considered extremely statistically significant.
RESULTS
DIFFERENTIAL USAGE OF GERMLINE VH, DH, AND JH GENES IN HUMAN
IgH GENE SEQUENCES
We have developed a Java-based VHRFA computer program to
analyze large number of IgH gene sequences and to identify poten-
tial VH replacement products (42). In the current study, the 61,851
human IgH gene sequences were downloaded from the NCBI
database. The initial analysis showed that 54,970 IgH genes have
identifiable VH, DH, and JH gene segments. After removal of dupli-
cate IgH sequences, the remaining 39,438 unique IgH genes with
identifiable VH, JH, and DH genes were further analyzed. The
usages of the VH, JH, and DH germline genes in these sequences
represent a combinatorial view of the human IgH repertoire from
many studies (Figure 1). The usages of all the 44 functional human
germline VH genes were confirmed in this dataset (Figure 1A); the
frequencies of individual VH germline gene usage varied consider-
ably. For different families of VH genes, theVH3 family of genes was
predominantly utilized, followed by the VH4 and VH1 families of
genes (Figure 1A). Such results are consistent with previous analy-
ses of small groups of IgH gene sequences, Among individual VH
genes, the VH3–23 gene was used the most frequently in 9536 IgH
genes (25%). The VH4–28 gene was used less frequently, which was
only found in 13 IgH rearrangements (0.03%). The differential
usages of individual VH germline genes did not seem to corre-
late with their relative location within the IgH locus (Figure 1A).
Within the IgH locus, the VH1–24, VH2–26, and VH3–30 genes are
located very close to the VH3–23 and VH4–28 genes. However, the
frequency of the VH3–23 gene usage is only 4-fold higher than those
of the VH3–30 gene, but is 50- and 80-fold higher than that of the
VH1–24 and VH2–26 genes, respectively (Figure 1A).
Among different DH genes, the DH3 gene family was predom-
inantly used in 35% of IgH genes, in which the DH3–10, DH3–3,
and DH3–22 genes were used frequently; The DH1 gene family
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FIGURE 1 |The comprehensive analysis of human IgH repertoire. The
61,851 human IgH gene sequences were downloaded from the NCBI database
on May, 2012. The sequences were first analyzed for their VH, DH, and JH gene
usage using the IMGT/V-Quest program and the identical sequences were
removed. The frequencies of VH (A), DH (B), and JH (C) germline gene usages
in the 39,438 unique human IgH gene sequences were shown.
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was used less frequently (Figure 1B). Among JH germline genes,
the JH4 gene was predominantly used followed by the JH6 gene
(Figure 1C). These results are consistent with previous individual
reports with small number of IgH sequences. Taken together, this
analysis provides a comprehensive view of the existing human IgH
gene sequences in the NCBI database.
IDENTIFICATION OF VH REPLACEMENT PRODUCTS USING THE VHRFA
PROGRAM
To identify potential VH replacement products in a large num-
ber of IgH gene sequences, the VHRFA program first generated
libraries of potential VH replacement footprint database with dif-
ferent length based on the VH gene 3′ ending sequences following
the conserved cRSS sites of all the functional human VH germline
genes (Tables S1 and S2 in Supplementary Material). Then, the
VHRFA program uses these libraries to search for the presence of
VH replacement footprint motifs with specified lengths at the VH–
DH junction (N1) regions or the DH–JH junction (N2) regions
of IgH genes. As an initial test of the newly developed VHRFA
program, we reanalyzed the 417 human IgH gene sequences that
had been to manually identify potential VH replacement products
analyzed in a previous study (37). The VHRFA program efficiently
identified VH replacement footprint motifs with 3, 4, 5, 6, or 7
nucleotides in both the N1 and N2 regions (Table 1, top). The fre-
quencies of VH replacement footprint motifs with 3, 4, or 5-mer in
the N1 regions are significantly higher than those in the N2 regions
(Table 1, top), indicating that the addition of such motifs in the
N1 region is not a random event. Based on the identification of
5-mer VH replacement footprints, 7.3% of the IgH gene sequences
can be assigned as potential VH replacement products. Further
review of these IgH genes confirmed the identified pentameric
VH replacement motifs within the VH–DH junctions (Table 2, N1
regions). If we consider the 4- or 3-mer VH replacement footprints
within the N1 regions, 25 or 54.7% of IgH genes can be assigned
as potential VH replacement products, respectively (Table 1; Table
S3 in Supplementary Material). These results are consistent with
our previously manual assignment of VH replacement products
in this group of IgH genes and provide the first validation of the
VHRFA program.
CONTRIBUTION OF VH REPLACEMENT PRODUCTS TO THE HUMAN IgH
REPERTOIRE
With the help of the VHRFA program, we searched for poten-
tial VH replacement products in the 39,438 unique human IgH
sequences with identifiable VH, DH, and JH genes from the NCBI
database. We first compared the frequencies of VH replacement
footprint motifs with 3, 4, 5, 6, or 7 nucleotides within the N1
and N2 regions (Table 1, bottom). The frequencies of 3, 4, 5, 6,
and 7-mer VH replacement footprint motifs in the N1 regions
are extremely statistically significantly higher than those in the N2
regions (Table 1, bottom, p< 0.0001), indicating that the presence
of such motifs at the N1 region is likely contributed by VH replace-
ment rather than random nucleotide addition. Among these IgH
gene sequences, 12.1% of them contain the 5-mer VH replacement
footprint motifs and can be assigned as potential VH replacement
products (Table 1, bottom). This number indicates a significant
contribution of VH replacement products to the diversification
of the human IgH repertoire. If we consider the 4- and 3-mer VH
Table 1 | Frequencies of VH replacement footprint motifs in the N1 and N2 regions of human IgH genes.
Total
number of
sequences
Sequences with
VH, DH, JH gene
assignmenta
Length of
VH replacement
footprint
VH replacement
footprint
motifs in N1
VH replacement
footprint
motifs in N2
p-Valueb Frequency of
VH replacement
products (%)c
Test IgH sequencesd 417 396 3 217 140 0.0001 54.7
4 99 64 0.0028 25.0
5 29 15 0.0437 7.3
6 5 3e NAf NAf
7 2 0 NAf NAf
NCBI IgH sequencesg 61,851 39,438 3 23,195 20,699 0.0001 58.8
4 13,365 11,240 0.0001 33.9
5 4788 3499 0.0001 12.1
6 1490 813 0.0001 4.3
7 382 140 0.0001 1.1
aUnique IgH gene sequences with identifiable VH, DH, and JH genes were analyzed. These IgH sequences contain both functional and non-functional IgH
rearrangements. N1, VH–DH junction regions; N2, DH–JH junction regions.
bThe frequencies of VH replacement footprint motifs with different length within the N1 or the N2 regions were compared by two-tailed Chi square with Yates’
correction. p<0.05 is considered statistically significant and p<0.0001 is considered extremely statistically significant.
cThe frequency of VH replacement products was calculated using the number of sequences with VH replacement motifs with different length in the N1 regions divided
by the total number of unique IgH gene sequences.
dThese IgH gene sequences had been analyzed manually for VH replacement products (37).
eAll the three 6-mer footprints within the N2 regions could be due to second DH gene segments.
fNot applicable.
gThe human IgH gene sequence dataset was downloaded from the NCBI database on April 20, 2011.
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Table 2 | Identification of potential VH replacement products in human IgH sequences.
Accession No. VH gene VH P N1a P DH CDR3 (aa)b
AF235818 VH1-69*06 tgtgcgaga gaagcaaagtttgagaag gctgccaaacc AREAKFEKAAKPYYYYGMDV
AF235903 VH3-33*01 tgtgcgagaga cagac agctgctgctgg ARDRQLLLGYGMDV
AF235823 VH3-11*01 tgtgcgagaga caccctcacgaaatcacc ttacgatttttggagtggttattat ARDTLTKSPYDFWSGYYGLTYYYYGMDV
AF235857 VH3-23*01 tgtgcgaaaga t gaagaggag tattgtggtagaaccagctgct AKDEEEYCGRTSCFCMDV
AF235601 VH1-18*01 tgtgcgagaga cgacggacgggcggcgg attgtagtggtggtagctgctactcc ARDDGRAADCSGGSCYSDY
AF235609 VH3-33*05 tgtgcgaga agagggccaatcc atatcagcagctgg ARRGPIHISSWYYYYYGMDV
AF235766 VH3-30*03 tgtgcga aacagtggacgc atattgtgg AKQWTHIVVFDI
AF235806 VH3-15*01 tgt cattcggggggtagacc gtatagcagtggctggt HSGGRPYSSGWSPKWYYGMDV
AF235787 VH3-23*01 tgtgcgaaaga tc aacctcgaaag gcagcagctggta AKDQPRKAAAGMYYYGMDV
AF235574 VH4-59*07 tgtgcgaga cgaaat tattactatgatagtagtggt ARRNYYYDSSGPDAFDI
AF235726 VH1-69*06 tgtgcg gggagaggagagtat ggctatagcagcagctgg AGRGEYGYSSSWFDY
AF235869 VH2-70*10 tgtgc cagaca atattgtggtggtgactgct ARQYCGGDCCSDY
AF235809 VH4-39*07 tgtgcga caaaatc c gtattacgatattttgactggttatt ATKSVLRYFDWLLPSYYYYYGMDV
AF235610 VH3-30-3*01 tgtgcgaga gatgaaag tagcagtggctgg ARDESSSGWYWYFDL
AF235541 VH3-48*03 tgtgcgagaga tc gacgcgaccggat taactgggga ARDRRDRINWGYYYGMDV
AF235758 VH2-70*01 tgtgcacggata agggccctagacgta aactgggga ARIRALDVNWGGWYFDL
AF235544 VH3-66*01 tgtgcgagaga tc gagac tacgatttttggagtggtt ARDRDYDFWSGYAFDI
AF235692 VH3-33*01 tgtgcgagaga gggggagattgat catattgtggtggtgactgctatccc AREGEIDHIVVVTAIPNWFDP
AF235764 VH1-3*01 tgtgcgagag cgaga ct aggatattgtagtggtggtagctgctactcc ARARLGYCSGGSCYSGGFDY
AF235793 VH1-69*02 tgtgcgaga gatctcacttacgggc attttgactggtta ARDLTYGHFDWLPPHYYYYYGMDV
AF235897 VH3-21*01 tgtgcgaga tcaacggcatca tacggtgactac ARSTASYGDYDNWFDP
AF235796 VH3-30*03 tgtgcgaaaga tc ctacgggaaccacaaacttatctcccttagggcg agcagcagct AKDPTGTTNLSPLGRAAAYVYYYYYGMDV
AF235588 VH4-59*08 tgtgcga cccatcggat taactgggga ATHRINWGFDY
AF235907 VH5-51*01 tgtg tgcgagacagctcg tacagctatggtt VRDSSYSYGLSNLYYYGMDV
AF235842 VH3-23*01 tgtgcgaaaga t ttcccagacgagcccgg gtaccagctgctatac AKDFPDEPGYQLLYGSLDY
AF235812 VH5-a*01 tgtgcgag ggccgaaatcttatccgg agcagtggc ARAEILSGAVAPRDY
AF235657 VH5-51*01 tgtgcgagac gagaacaacc tgggacccact ARREQPGTHLNY
AF235626 VH3-21*01 tgtggga aagaggacc ggagttatta GKEDRSYYDY
AF235565 VH3-23*01 tgt accacagacccggccttgaggacctc actgctggggt TTDPALRTSLLGSFDY
aThe identified VH replacement footprints are underlined and highlighted in red in the N1 regions.
bThe amino acids encoded by the identified VH replacement footprints are underlined in the amino acid sequences of the CDR3 regions.
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replacement footprints motifs, 33.9 and 55.8% of IgH genes can be
assigned as potential VH replacement products (Table 1, bottom).
Within the large number of IgH genes, there are 3818 non-
functional IgH gene sequences and 687 of them contain the 5-mer
VH replacement footprint motifs in their N1 regions, which can
be assigned as potential VH replacement products. The frequency
of VH replacement products in non-functional IgH genes (18%)
is extremely statistically significantly higher than that in the over-
all functional IgH genes (p< 0.0001, two-tailed Chi square test
with Yates’ correction). Identification of VH replacement prod-
ucts in non-functional IgH genes fulfills the prediction that VH
replacement is a random process that can generate both func-
tional and non-functional IgH rearrangement products. Taken
together, these results uncovered a previously unrealized contribu-
tion of VH replacement products to the diversification of human
IgH repertoire.
DISTRIBUTION OF VH REPLACEMENT PRODUCTS IN IgH GENES USING
DIFFERENT VH GENES
Using the VHRFA program, we further analyzed the distribution
of VH replacement products in IgH genes using different VH genes.
The frequencies of VH replacement products in IgH genes using
different VH germline genes are different (Figure 2). For exam-
ples, the frequencies of VH replacement products in IgH genes
using the VH2–5, VH3–30, VH3-30-3, VH1–69, and VH3–34 genes are
23.88, 19.12, 16.64, 14.28, and 13.13%, which are extremely statis-
tically significantly higher than that in IgH genes using the VH6-1
gene (p< 0.0001, two-tailed Fisher’s exact test) (Figure 2). As an
internal control, 7.56% of IgH genes using the VH6-1 gene have
5-mer VH replacement footprints within their N1 regions, which
is statistically significantly lower than that in the overall IgH gene
sequences (p= 0.0004, two-tailed Fisher’s exact test).
VH REPLACEMENT PRODUCTS ARE HIGHLY ENRICHED IN IgH GENES
DERIVED FROM PATIENTS WITH AUTOIMMUNE DISEASES OR VIRAL
INFECTIONS
The overall frequency of VH replacement products in the 39,438
unique IgH genes from the NCBI database (12.1%) is much
higher than what was estimated in the 417 IgH genes obtained
from healthy donors. We reasoned that the majority of IgH
gene sequences deposited at the NCBI database was derived
from diseased subjects, which may have higher frequencies of
VH replacement products. Next, we investigated the distribution
of VH replacement products in IgH genes derived from differ-
ent disease sub-categories. Using the keyword analysis function
within the VHRFA program, we can correlate the frequencies of
VH replacement products with different sub-categories of IgH
gene sequences from the NCBI database. For examples, the fre-
quency of VH replacement products in 558 IgH genes derived
from healthy donors is 8.6% (Figure 3), which is similar to
the result obtained from previous analysis of the 417 IgH gene
sequences from healthy donors. Interestingly, the frequencies of
VH replacement products in IgH genes derived from subjects with
different autoimmune diseases, such as allergic rhinitis, RA, and
SLE are statistically significantly higher than that in the healthy
donors (Figure 3, p< 0.05, two-tailed Chi square test with Yates’
correction; Table S4 in Supplementary Material). The frequencies
of VH replacement products are further enriched in IgH genes
derived from RA synovium and in IgH genes encoding rheuma-
toid factors, suggesting that B-cells expressing VH replacement
products are positively selected in the RA synovium to encode
rheumatoid factors (Figure 3, p< 0.05, two-tailed Chi square test
with Yates’ correction; Table S4 in Supplementary Material). Sim-
ilarly, VH replacement products are highly enriched in IgH genes
derived from SLE plasmablasts (Figure 3, p< 0.05, two-tailed
Chi square test with Yates’ correction; Table S4 in Supplementary
Material), suggesting that these enriched VH replacement products
contribute to the production of autoAbs in SLE.
The accumulation of VH replacement in IgH genes derived
from patients with different autoimmune diseases suggested that
VH replacement products may contribute to the production of
autoAbs. Indeed, further analyses showed that VH replacement
products are statistically significantly enriched in IgH genes encod-
ing rheumatoid factors, anti-Rh (D) Abs, and anti-acetylcholine
receptor Abs (Figure 3, p< 0.05, two-tailed Chi square test with
Yates’ correction; Table S4 in Supplementary Material).
To our surprise, the frequencies of VH replacement products
are significantly elevated in IgH genes derived from different
viral infections. For examples, the frequencies of VH replace-
ment products in IgH genes derived from HIV and HCV infected
patients are statistically significantly higher than that in healthy
donors (Figure 3, p< 0.05, two-tailed Chi square test with Yates’
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FIGURE 2 | Distribution of VH replacement products in IgH genes using
different VH genes. The frequencies of VH replacement products in functional
IgH genes using each VH germline genes are compared with that in IgH genes
using the VH6-1 gene. **p< 0.0001, *p<0.05. The result for IgH genes using
the VH6-1 gene is highlighted in the box and the frequency of VH replacement
products in all the IgH genes is indicated by the dashed line.
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FIGURE 3 | VH replacement products are significantly enriched in IgH
genes derived from autoimmune diseases or viral infections and in IgH
genes encoding autoreactive or anti-viral Abs. Frequencies of VH
replacement products in IgH gene sequences derived from different
sub-categories were analyzed based on the identification of pentameric VH
replacement footprints within their V–D junctions. The frequencies of VH
replacement products in IgH genes derived from different autoimmune
diseases and viral infections, or in IgH genes encoding auto Abs, anti-viral
Abs, or anti-bacterial Abs were compared with that from healthy controls.
The number of analyzed IgH gene sequences in each subcategory are
indicated (n). The arrow head indicates the overall frequency of VH
replacement products (12.1%) in the 39,438 unique human IgH sequences.
Statistical significance was determined using a two-tailed Chi square test
with Yate’s correction. *p<0.05 is considered statistically significant and
**p<0.0001 is considered extremely statistically significant.
correction; Table S4 in Supplementary Material). Further analy-
ses showed that the VH replacement products contribute to about
30% of IgH genes encoding anti-HCV glycoprotein E2 Abs or anti-
HBVsAg Abs. Such frequencies are statistically significantly higher
than that in healthy donors (Figure 3, p< 0.05, two-tailed Chi
square test with Yates’ correction). Taken together, these results
showed that VH replacement products are highly enriched in IgH
genes derived from patients with different autoimmune diseases
and viral infections.
VH REPLACEMENT ELONGATES THE IgH CDR3
VH replacement renews almost the entire VH coding region. Due
to the location of the cRSS site, a short stretch of nucleotides
is remained as a VH replacement footprint at the newly formed
VH–DH junction after the VH replacement process (37). Such
VH replacement footprints can contribute up to two amino acids
into the IgH CDR3 to elongate the CDR3. The average CDR3
length of the identified VH replacement products is 18.2± 5.0
aa (n= 4417), which is extremely statistically significantly longer
than that of the non-VH replacement products (15.4± 4.4 aa,
Figure 3, p< 0.0001, unpaired t -test) (Figure 4). This result
confirmed that VH replacement elongates the IgH CDR3 region.
THE VH REPLACEMENT FOOTPRINTS PREFERENTIALLY ENCODE
CHARGED AMINO ACIDS
Our previous analysis showed that the VH replacement footprints
preferentially encoded charged amino acids in the IgH CDR3
regions (37, 45). This is likely predetermined by the conserva-
tion of amino acid sequence at the 3′ ends of VH germline genes.
Here, analysis of the amino acids encoded by the identified pen-
tameric VH replacement footprints in the 4417 VH replacement
products showed that 57% of them are charged amino acids.
Such frequency is extremely statistically significantly higher than
that in the N1 regions of non-VH replacement products (25%)
(Figure 5A, p< 0.0001, two-tailed Chi square test with Yates’ cor-
rection). Detailed analyses showed that the frequencies of K, R,
D, and E residues encoded by the VH replacement footprints
are statistically significantly higher than their usage in the N1
regions of non-VH replacement products (Figure 5B, p< 0.05,
two-tailed Chi square test with Yates’ correction). These results
confirmed our previous prediction that VH replacement footprints
preferentially contribute charged amino acids to the IgH CDR3
regions.
VH REPLACEMENT PRODUCTS ARE POSITIVELY SELECTED DURING
AUTOIMMUNE OR ANTI-VIRAL RESPONSES
Charged amino acids within IgH CDR3 are not well tolerated dur-
ing Ab repertoire development, they are frequently found within
the IgH CDR3 regions of autoreactive or anti-viral Abs, which
may play important roles in binding charged self or viral anti-
gens, respectively. Further analyses of VH replacement products
derived from different autoimmune diseases or viral infections
showed that the identified VH replacement footprints predomi-
nantly encode charged amino acids (Figure 6A). Detailed analyses
showed that the identified VH replacement footprints in IgH genes
encoding anti-DNA/histone Abs or rheumatoid factors encoded
significantly lower frequencies of negatively charged residues,
including D, E, N, and Q residues (Figure 6B, p< 0.05, two-tailed
Chi square test with Yates’ correction).
The identified VH replacement products have similar muta-
tion rate when compared with the non-VH replacement product
derived from healthy donors, patients with autoimmune diseases
or viral infections (Figure 6C). As negative controls, VH replace-
ment products or non-VH replacement products in neonatal IgH
gene sequences have much lower mutation rates (Figure 6C).
The accumulation of mutations within these VH replacement
products indicates that these enriched VH replacement products
in autoimmune diseases or viral infections had been positively
selected.
DISCUSSION
In order to determine the distribution of VH replacement prod-
ucts in these IgH genes and explore the biological significance of
VH replacement products in human antibody diversification and
diseases, we developed a Java based computer program VHRFA
to analyze large number of IgH gene sequences and to identify
potential VH replacement products (42). Previous analyses of the
IgH gene repertoire have provided important insights regarding
the developmental process and function of B lineage cells. Due
to the tremendous diversity, the complete human IgH repertoire
cannot be experimentally determined. Within the NCBI database,
there are 61,851 human IgH gene sequences (May, 2012 version).
The initial analysis of the VH, DH, and JH gene usages in the 61,851
human IgH gene sequences provides a comprehensive view of the
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significant. **p<0.0001 is considered extremely statistically significant.
human IgH repertoire. In this dataset, the usage of every func-
tional VH germline gene was confirmed, although their usages
differ dramatically.
Using theVHRFA program,we identifiedVH replacement prod-
ucts and analyzed their distributions in the 39,438 unique IgH
sequences. Based on the identification of pentameric VH replace-
ment footprint motifs within the VH–DH junctions, 12.1% of the
IgH genes can be assigned as potential VH replacement products.
These results confirmed our previous estimation that VH replace-
ment products contribute to the diversification of the human IgH
repertoire. Interestingly, the frequencies of VH replacement prod-
ucts in IgH genes using theVH2–5,VH3–30,VH3-30-3,VH3–49,VH1–69,
and VH3–34 are statistically significantly higher than that in the
overall IgH genes. In contrast, the frequency of VH replacement
products in IgH genes using the VH6-1 gene is statistically sig-
nificantly lower than that in the overall IgH genes. Among the
non-functional IgH genes, 18% of them contain the pentameric
VH replacement footprints and can be assigned as potential VH
replacement products. These results confirmed the prediction that
VH replacement is a random process that can generate both func-
tional and non-functional IgH rearrangements. Moreover, the
high frequency of VH replacement products in non-functional
IgH genes suggested that VH replacement products were nega-
tively selected during B-cell development. Based on this reasoning,
the frequency of VH replacement products in the non-functional
IgH genes may represent the true frequency of VH replacement
during early stages of B-cell development, because these non-
functional IgH rearrangements cannot encode BCRs and had not
been selected during B-cell development.
Due to the location of the cRSS site, a short stretch of
nucleotides has the potential to remain as a VH replacement
footprint at the VH–DH junctions following the VH replacement
process (25, 37, 46). The leftover VH replacement footprints will
elongate the IgH CDR3 regions (25, 37, 46). Analyses of the identi-
fied 4788 VH replacement products showed that the average CDR3
length of the identified VH replacement products is 2.8 aa longer
than that of non-VH replacement products. Previously, it surprised
us that the identified VH replacement footprints preferentially
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FIGURE 6 | VH replacement footprints preferentially contribute charged
amino acids into the CDR3 regions of IgH genes derived from
autoimmune diseases and viral infections. (A) Frequencies of charged and
uncharged amino acids encoded by the VH replacement footprints in IgH
genes derived from autoimmune diseases and viral infections. n, Total number
of amino acids analyzed in each subcategory. (B) Frequencies of negatively
and positively charged residues encoded by the VH replacement footprints in
IgH genes derived from autoimmune diseases or viral infections. Statistical
significance was determined using a two-tailed Chi square test with Yate’s
correction. *p<0.05 is considered statistically significant. (C) Comparison of
overall somatic mutation rates (%) within VH region of VH replacement
products versus non-VH replacement products in different sub-categories.
encode charged amino acids within the IgH CDR3 regions (22,
37, 46). Recent analyses showed that the positions of the cRSS and
high frequencies of charged amino acids encoded by the follow-
ing nucleotides are highly conserved in IgH genes from different
vertebrates (47). In the current study, 57% of the identified VH
replacement footprints encoded charged amino acids in the IgH
CDR3 regions. Normally, charged amino acids within IgH CDR3
are not well tolerated during antibody repertoire development,
probably due to charged residues may generate autoAbs. Indeed,
our analysis revealed that VH replacement products are signifi-
cantly enriched in IgH genes derived from patients with different
autoimmune diseases, including RA, allergic rhinitis, and SLE or in
IgH genes encoding different autoAbs such as rheumatoid factor,
anti-rhesus D antigen, and anti-acetylcholine receptor Abs. Our
recent analyses of large number of mouse IgH genes also showed
that the frequencies of VH replacement products are enriched
in IgH genes derived from autoimmune prone mice (48). These
results suggested that VH replacement products contribute to the
generation of autoantibodies in both human and mouse.
Another important and interesting finding from this analysis
of large number of IgH gene sequences is that the frequencies of
VH replacement products are significantly elevated in IgH genes
derived from various viral infections, including HIV, HCV, and
in IgH genes encoding Abs against HCV glycoprotein E2 or HBV
surface antigens. Our recent studies showed that VH replacement
products are highly enriched in IgH genes encoding different sub-
groups of anti-HIV antibodies, especially in CD4i and PGT anti-
bodies (49). These results suggested that VH replacement products
may contribute to the generation of anti-viral Abs. The major-
ity of the VH replacement footprints identified from anti-viral
Abs also encode charged amino acids, which may be important
for binding charged viral antigens. Moreover, the accumulation
of mutations in these VH replacement products indicated that
these enriched VH replacement products in patients with viral
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infections are positively selected during anti-viral responses. The
identification of VH replacement products in autoimmune dis-
eases and anti-viral responses suggested a potential link between
viral infections and the pathogenesis of autoimmune diseases. It
has long been postulated that chronic viral infections contribute
to autoimmunity. However, clear examples that Abs against viral
antigens cross-react with self-antigens have only been found in
a few cases (50, 51). Here, our results reveal a shared pattern of
accumulation of VH replacement products in IgH genes derived
from autoimmune diseases and anti-viral responses.
VH replacement was originally proposed as a receptor editing
mechanism to change unwanted IgH genes that are either non-
functional or encoding autoreactive Abs. The enrichment of VH
replacement products in IgH genes derived from autoimmune dis-
eases or encoding autoAbs is particular puzzling. There are several
possible mechanisms to explain this finding. First, we have recently
shown that crosslinking cell surface BCRs induces VH replacement
in human immature B-cells (40). Thus, the levels of VH replace-
ment recombination might be induced in the immature B-cells
during either the anti-viral immune response or autoimmune
disease due to persistent antigen stimulation or chronic inflam-
mation. In supporting of this assumption, the number of newly
emigrated immature B-cells in the peripheral blood is increased
during inflammatory response; and these mobilized immature B-
cells may continue to undergo VH replacement recombination
ectopically. Second, the intrinsic feature of VH replacement is elon-
gating the IgH CDR3 with charged amino acid. VH replacement
products may frequently encode autoAbs and they are efficiently
deleted during normal B-cell development. The observed elevated
frequencies of VH replacement products in different autoimmune
diseases may reflect the defective negative selection in these dis-
eased subjects. Moreover, ectopically occurred VH replacement
may bypass the stringent negative selection in the bone marrow
and release VH replacement products in the periphery. Last, due
to the special features of VH replacement products in generat-
ing IgH genes with long and charged CDR3, it is possible that
VH replacement products are positively selected by viral antigens
during anti-viral responses to produce specific anti-viral Abs. In
supporting of this notion, the identified potential VH replace-
ment products encoding anti-HIV antibodies all have very long
CDR3 regions with multiple charged amino acid residues (49).
The accumulated mutations within the VH genes of the identi-
fied VH replacement products in the current study also indicated
the positive selection. However, the leftover VH replacement prod-
ucts generated during a chronic viral infection may encode Abs
that cross-react with self-antigens and later contribute to autoim-
munity. In fact, many cell surface antigens and viral antigens are
negatively charged, which may be a reason for the selection of VH
replacement products with long and charged CDR3 regions.
In our sequence based analysis, the assignment of VH replace-
ment is dependent on the identification of VH replacement foot-
prints within the VH–DH junctions. Any deletion at the 3′ of VH
genes or the 5′ of VH replacement footprint motifs during the
primary or secondary IgH gene recombination, respectively, may
destroy the pentameric VH replacement footprints. Therefore, it
is possible that the sequence analysis based study still under-
estimates the frequency of VH replacement products. Using the
VHRFA program, we extended our analysis our VH replacement
products to include potential VH replacement footprint motifs
with different lengths. For examples, 33.9% of the IgH genes con-
tain the tetrameric VH replacement footprint motifs and 58.8% of
IgH genes contain the trimeric VH replacement footprint motifs.
These results revealed a significant contribution of VH replacement
products to the IgH repertoire. Recent studies in mice carrying
non-functional IgH genes on both IgH alleles demonstrated that
VH replacement occurs efficiently to generate almost normal num-
bers of B-cells with diversified IgH repertoires (52). However, only
about 20% of the IgH gene sequences from this study contained
residual VH replacement footprints. Therefore, the majority IgH
genes generated through VH replacement recombination have no
leftover VH replacement footprints. Theoretically, 66% of IgH
rearrangements will be out of reading frame and 44% of devel-
oping B-cells may carry non-functional IgH rearrangements on
both alleles. If all of these B-cells are rescued by VH replacement,
a minimum of 44% of the IgH genes might be generated through
VH replacement recombination. Under this assumption, IgH genes
containing the tetrameric or the trimeric VH replacement foot-
print motifs at their N1 regions should also be considered as
potential VH replacement products.
Like any sequence based analysis program, the VHRFA program
also has its limitation. Although sequence motifs assemble the VH
gene 3′ ending sequences can be identified in the N1 regions, such
motifs can also be identified within the N2 regions at relative
lower frequencies. Theoretically, VH replacement can only leave
footprint within the N1 region; the existence of VH replacement
footprint like motifs within the N2 regions can only be generated
by random nucleotide addition. For IgH genes using the VH6-1
gene, which is the first VH germline gene 5′ to the DH locus, there
should have no VH replacement footprint like motifs within the
VH–DH junctions, but the VHRFA program still identifies 7.56%
of the sequences contains VH replacement footprint like motifs
within the VH–DH junctions. We can only refer such motifs as the
contribution of random nucleotide addition.
In summary, analyses of a large number of human IgH gene
sequences from the NCBI database uncovered a significant con-
tribution of VH replacement products to human Ab repertoire,
especially in IgH genes derived from autoimmune diseases or
anti-viral responses. Understanding how VH replacement is reg-
ulated and how VH replacement products are positively or neg-
atively selected during normal or diseased conditions will be the
focus of future studies, because modulation of the level of VH
replacement may offer unique approaches to treat different human
diseases.
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